Sosei Group Corp
TSE:4565
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sosei Group Corp
Operating Income
Sosei Group Corp
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sosei Group Corp
TSE:4565
|
Operating Income
-¥8.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Operating Income
¥480.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Operating Income
¥317.4B
|
CAGR 3-Years
61%
|
CAGR 5-Years
34%
|
CAGR 10-Years
11%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Operating Income
¥419.7B
|
CAGR 3-Years
35%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Operating Income
¥620.9B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
16%
|
CAGR 10-Years
22%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Operating Income
¥394.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
19%
|
CAGR 10-Years
5%
|
|
Sosei Group Corp
Glance View
Sosei Group Corp. engages in the discovery, design, and development of medicines targeting G protein-coupled receptors (GPCRs). The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 198 full-time employees. The company went IPO on 2004-07-29. The pharmaceutical business is engaged in the research, development and sales of medicines, the management of regenerative medical funds, the investment in bio venture companies related to regenerative medicine, the overseas development by licensing, the promotion of commercialization, the structural analysis of GPCR, the initial lead compound creation, the candidate search by proprietary StaR technology, as well as structural base of new drugs using GPCR related basic technology drug discovery, screening, promotion of antibody drug research and development.
See Also
What is Sosei Group Corp's Operating Income?
Operating Income
-8.9B
JPY
Based on the financial report for Dec 31, 2025, Sosei Group Corp's Operating Income amounts to -8.9B JPY.
What is Sosei Group Corp's Operating Income growth rate?
Operating Income CAGR 1Y
-34%
Over the last year, the Operating Income growth was -34%.
